Erasca (ERAS) Stock Price, News & Analysis

Company Overview

Erasca, Inc. is a clinical-stage biotechnology company focused on developing treatments for cancers driven by abnormalities in the RAS/MAPK signaling pathway. The company’s research and development strategy is centered on precision oncology, with the goal of addressing cancers that have historically been difficult to treat because of mutations in RAS and related proteins.

Erasca’s lead investigational program is daraxonrasib, also known as RMC-6236, an oral RAS(ON) multi-selective inhibitor designed to target active RAS proteins. The therapy has been evaluated in clinical studies involving advanced solid tumors, including pancreatic ductal adenocarcinoma, non-small cell lung cancer and colorectal cancer. The company has also developed additional programs aimed at targets within the RAS/MAPK pathway, including investigational agents directed at specific RAS mutations and pathway regulators.

Founded in 2018 and headquartered in San Diego, California, Erasca conducts research and clinical development activities intended to serve patients with advanced cancers in the United States and other markets where its trials and programs are available. The company was co-founded by Jonathan Lim, M.D., a biotechnology executive and physician-scientist who has served as Erasca’s chief executive officer and chairman. As a clinical-stage biotechnology company, Erasca’s programs remain investigational and are subject to clinical, regulatory and commercial development.

Key Stats

• Today's Range: $14.51 to $15.47
• 50-Day Range: $14.77 to $21.26
• 52-Week Range: $1.75 to $24.28
• Volume: 8.69 million shs
• Average Volume: 4.23 million shs
• Market Capitalization: $5.17 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.09
• Consensus Rating: Moderate Buy

Erasca Stock Analysis - MarketRank™

Erasca scored higher than 42% of companies evaluated by MarketBeat, and ranked 598th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Erasca has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on no strong buy ratings, 8 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Erasca has a consensus price target of $22.09, representing about 49.6% upside from its current price of $14.77.

Amount of Analyst Coverage

Erasca has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Erasca are expected to decrease in the coming year, from ($0.49) to ($0.65) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Erasca is -15.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Erasca is -15.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Erasca has a P/B Ratio of 14.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.41% of the float of Erasca has been sold short.

Short Interest Ratio / Days to Cover

Erasca has a short interest ratio ("days to cover") of 9.44.

Change versus previous month

Short interest in Erasca has recently increased by 1.27%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Erasca does not currently pay a dividend.

Dividend Growth

Erasca does not have a long track record of dividend growth.

News and Social Media

• Score: 1.2 / 5
• News Sentiment: -0.03

News Sentiment

Erasca has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Erasca this week, compared to 9 articles on an average week.

Search Interest

Only 1 people have searched for ERAS on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Erasca to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Erasca insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.20% of the stock of Erasca is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

67.78% of the stock of Erasca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 9/19/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ERAS
• CIK: 1761918
• Web: www.erasca.com
• Phone: 858-465-6511
• Fax: N/A
• Employees: 103
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Erasca: $22.09
• High Price Target: $30.00
• Low Price Target: $16.00
• Potential Upside/Downside: +49.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.64
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.95)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$124.55 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -38.43%
• Return on Assets: -32.05%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.29
• Quick Ratio: 8.29

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.05 per share
• Price / Book: 14.07

Miscellaneous

• Outstanding Shares: 349,760,000
• Free Float: 300,096,000
• Market Cap: $5.17 billion
• Optionable: Optionable
• Beta: 0.64